Late acquisition of BCR::ABL1 during clonal evolution of SAMD9-associated MDS with phenotypic shift from AML to B-ALL [0.03%]
SAMD9相关MDS克隆演化过程中BCR-ABL1的获得以及表型从AML向B-ALL转化
Yusuke Nakata,Anna Hiratsuka,Takeshi Yoroidaka et al.
Yusuke Nakata et al.
We describe a unique case of SAMD9-associated myelodysplastic syndrome (MDS) with monosomy 7 that evolved over 16 years into BCR::ABL1-positive acute myeloid leukemia (AML) and subsequently manifested as B-cell acute lymphoblastic leukemia ...
Post-marketing surveillance of fostamatinib for primary immune thrombocytopenia in Japan: interim analysis [0.03%]
日本成人特发性免疫性血小板减少症患者氟西马替尼上市后监测的中期分析
Masataka Kuwana,Shoichi Yoshioka,Maki Wakabayashi et al.
Masataka Kuwana et al.
Fostamatinib was approved in Japan in December 2022 for primary immune thrombocytopenia (ITP). Given the limited clinical trial data, post-marketing surveillance (PMS) was conducted in Japan to collect safety and effectiveness data for fost...
Characteristics of progressive multifocal leukoencephalopathy in hematological malignancies, With reference to HIV-infected patients [0.03%]
血液系统恶性肿瘤进展性多灶性白质脑病的临床特征与艾滋病患者的对比研究
Emi Yokoyama,Taisuke Harada,Tomoyuki Endo et al.
Emi Yokoyama et al.
Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection of the central nervous system (CNS) observed in immunocompromised individuals. We retrospectively evaluated the clinical courses of PML in patients with hema...
Improved post-transplant outcomes following inotuzumab ozogamicin-based salvage therapy in relapsed/refractory B-ALL: a real-world retrospective study [0.03%]
基于依鲁替尼清淋的复发/难治性B细胞急淋移植前挽救治疗可改善移植疗效：真实世界回顾研究
Ryo Koizumi,Shinsuke Takagi,Aya Nishida et al.
Ryo Koizumi et al.
Relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) remains challenging, and allogeneic hematopoietic cell transplantation (allo-HCT) is often the only curative option. Inotuzumab ozogamicin (InO) has demonstrated high re...
Early prediction of ICANS using CRS characteristics in B-cell lymphoma patients receiving CAR-T therapy [0.03%]
CAR-T治疗B细胞淋巴瘤患者中使用CRS特征进行ICANS的早期预测
Hakuei Nishihara,Fumiaki Jinnouchi,Daisuke Ishihara et al.
Hakuei Nishihara et al.
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a serious early adverse event of chimeric antigen receptor T (CAR-T) cell therapy. ICANS typically occurs concurrently with or follows cytokine release syndrome (CRS), sugges...
Evidence- and opinion-based consensus from Delphi round 1 of the Asian aplastic anemia recommendation development [0.03%]
亚急性期再生障碍性贫血治疗专家共识意见第1轮德尔菲调查结果
Jun Ho Jang,Yok Lam Kwong,Surapol Issaragrisil et al.
Jun Ho Jang et al.
Background: Implementing international guidelines for aplastic anemia (AA) in Asia remains challenging due to limited access to advanced diagnostic tools, restricted treatment options, and variation in healthcare policies...
Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms [0.03%]
与真性红细胞增多症和原发性血小板增多症患者肺动脉高压高风险相关的危险因素分析
Orly Leiva,Steven Soo,Olivia C Liu et al.
Orly Leiva et al.
Myeloproliferative neoplasms (MPNs) are associated with pulmonary hypertension (PH). Recent studies have demonstrated associations between PH and adverse cardiovascular outcomes and MPN disease progression. However, risk factors for develop...
Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy [0.03%]
克隆造血对接受CAR-T细胞治疗的多发性骨髓瘤患者的预后影响研究
Sophie G Carlson,Benjamin R Puliafito,Kosuke Kawai et al.
Sophie G Carlson et al.
Clonal hematopoiesis of indeterminate potential (CHIP) is the presence of hematologic malignancy-associated somatic mutations in patients without hematologic malignancies. In multiple myeloma (MM), the implications of CHIP on chimeric antig...
Qiuyang Li,Hongxia Wang,Yuqin He et al.
Qiuyang Li et al.
Allogeneic hematopoietic stem cell transplantation remains the standard treatment for various hematologic genetic disorders resulting from single or multiple genes. However, this strategy is hindered by two main problems: failure to find a ...
Therapeutic drug monitoring guides personalized ponatinib dose reduction for chronic myeloid leukemia [0.03%]
治疗药物监测引导慢性粒细胞白血病患者个性化减少 Ponatinib 剂量
Maiko Abumiya,Naoto Takahashi
Maiko Abumiya
The arterial occlusive events (AOEs) associated with ponatinib are dose-dependent. Although the phase II OPTIC trial showed that reducing the dose to 15 mg daily (QD) after achieving a response provided an optimal benefit-risk profile, this...